arvinas_logoART_lg.jpg
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 23, 2024 17:00 ET | Arvinas Inc.
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2...
arvinas_logoART_lg.jpg
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
May 16, 2024 06:00 ET | Arvinas Inc.
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in...
arvinas_logoART_lg.jpg
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 09, 2024 16:42 ET | Arvinas Inc.
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the...
arvinas_logoART_lg.jpg
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024 07:00 ET | Arvinas Inc.
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study...
arvinas_logoART_lg.jpg
Arvinas to Present at Upcoming Investor Conferences
May 02, 2024 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
April 24, 2024 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 11, 2024 07:00 ET | Arvinas Inc.
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01...
arvinas_logoART_lg.jpg
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
March 18, 2024 16:40 ET | Arvinas Inc.
NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
March 04, 2024 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 27, 2024 07:00 ET | Arvinas Inc.
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the...